IMMUNOVANT, INC. Earnings Per Share, Basic and Diluted
IMMUNOVANT, INC. (IMVT) reported Earnings Per Share, Basic and Diluted of -$1.22 per share for the 12-month period ending 2021-03-31, per its 10-K filed 2021-06-01.
Discontinued › Income Statement › Earnings Per Share
us-gaap:EarningsPerShareBasicAndDiluted · last filed 2021-06-01
- IMMUNOVANT, INC. earnings per share, basic and diluted for the quarter ending 2021-03-31 was -$0.29.
- IMMUNOVANT, INC. earnings per share, basic and diluted for the quarter ending 2020-12-31 was -$0.32.
- IMMUNOVANT, INC. earnings per share, basic and diluted for the quarter ending 2020-09-30 was -$0.25.
- IMMUNOVANT, INC. earnings per share, basic and diluted for the quarter ending 2020-06-30 was -$0.38.
- IMMUNOVANT, INC. earnings per share, basic and diluted for fiscal 2021 was -$1.22.
- IMMUNOVANT, INC. earnings per share, basic and diluted for fiscal 2020 was -$1.54.
- IMMUNOVANT, INC. earnings per share, basic and diluted for fiscal 2019 was -$1.29.
| Period end | Earnings Per Share, Basic and Diluted 3 month | Earnings Per Share, Basic and Diluted 3 month as first filed | Earnings Per Share, Basic and Diluted 6 month | Earnings Per Share, Basic and Diluted 9 month | Earnings Per Share, Basic and Diluted 12 month |
|---|---|---|---|---|---|
| 2021-03-31 | -$0.29 derived: net income ÷ weighted average shares · filed 2022-06-08 | -$0.61 derived: net income ÷ weighted average shares · filed 2022-06-08 | -$0.86 derived: net income ÷ weighted average shares · filed 2022-06-08 | -$1.22 10-K · filed 2021-06-01 | |
| 2020-12-31 | -$0.32 10-Q · filed 2021-02-16 | -$0.58 derived: net income ÷ weighted average shares · filed 2022-02-04 | -$0.94 10-Q · filed 2021-02-16 | -$1.30 derived: net income ÷ weighted average shares · filed 2022-02-04 | |
| 2020-09-30 | -$0.25 10-Q · filed 2020-11-12 | -$0.61 10-Q · filed 2020-11-12 | -$0.97 derived: net income ÷ weighted average shares · filed 2022-02-04 | -$1.27 derived: net income ÷ weighted average shares · filed 2022-02-04 | |
| 2020-06-30 | -$0.38 10-Q · filed 2020-08-12 | -$0.75 derived: net income ÷ weighted average shares · filed 2022-02-04 | -$1.06 derived: net income ÷ weighted average shares · filed 2022-02-04 | -$1.42 derived: net income ÷ weighted average shares · filed 2022-02-04 | |
| 2020-03-31 | -$0.38 derived: net income ÷ weighted average shares · filed 2021-06-01 | -$0.67 derived: net income ÷ weighted average shares · filed 2021-06-01 | -$1.04 derived: net income ÷ weighted average shares · filed 2021-06-01 | -$1.54 10-K · filed 2021-06-01 | |
| 2019-12-31 | -$0.28 10-Q · filed 2021-02-16 | -$0.65 derived: net income ÷ weighted average shares · filed 2021-02-16 | -$1.16 10-Q · filed 2021-02-16 | -$1.52 derived: net income ÷ weighted average shares · filed 2021-02-16 | |
| 2019-09-30 | -$0.38 10-Q · filed 2020-11-12 | $0.05 10-Q · filed 2019-11-13 | -$0.90 10-Q · filed 2020-11-12 | $0.07 10-Q · filed 2019-11-13 | -$1.49 derived: net income ÷ weighted average shares · filed 2021-02-16 |
| 2019-06-30 | -$0.52 10-Q · filed 2020-08-12 | $0.02 10-Q · filed 2019-08-12 | $0.02 10-Q · filed 2019-08-12 | -$1.11 derived: net income ÷ weighted average shares · filed 2021-02-16 | |
| 2019-03-31 | $0.00 10-Q · filed 2019-06-12 | -$0.45 derived: net income ÷ weighted average shares · filed 2020-02-14 | -$1.29 10-K · filed 2020-06-29 | ||
| 2018-12-31 | -$0.24 10-Q · filed 2020-02-14 | -$1.16 10-Q · filed 2020-02-14 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| CG Oncology, Inc. (CGON) | United States | $6.095B | -27.95 |
| Scholar Rock Holding Corp (SRRK) | United States | $5.920B | -16.37 |
| Vaxcyte, Inc. (PCVX) | United States | $8.466B | -7.91 |
| CRISPR Therapeutics AG (CRSP) | $5.390B | -11.68 | |
| ImmunityBio, Inc. (IBRX) | United States | $9.157B | -9.29 |
| IOVANCE BIOTHERAPEUTICS, INC. (IOVA) | United States | $4.897B | -6.51 |
| Adaptive Biotechnologies Corp (ADPT) | United States | $4.719B | -53.43 |
| Kymera Therapeutics, Inc. (KYMR) | United States | $9.631B | -31.69 |
| Relay Therapeutics, Inc. (RLAY) | United States | $3.884B | -14.30 |
| Krystal Biotech, Inc. (KRYS) | United States | $10.210B | 45.56 |